Alessandra Noto

Dr. Alessandra Noto

Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2018 in Journal of Virology
Verified
Journal Article
Open access
PDF file
Alessandra NotoAlessandra Noto
Alessandra Noto
FPFrancesco A. Procopio
Francesco A. Procopio
RBRiddhima Banga
Riddhima Banga
MSMadeleine Suffiotti
Madeleine Suffiotti
JCJean-Marc Corpataux
Jean-Marc Corpataux
GPGiuseppe Pantaleo
Giuseppe Pantaleo
A recent study conducted in blood has proposed CD32 as the marker identifying the “elusive” HIV reservoir. We have investigated the distribution of CD32+ CD4 T cells in blood and lymph nodes (LNs) of HIV-1-uninfected subjects and viremic untreated and long-term-treated HIV-1-infected individuals and their relationship with PD-1+ CD4 T cells. The frequency of CD32+ CD4 T cells was increased in viremic compared to treated individuals in LNs, and a large proportion (up to 50%) of CD32+ cells coexpressed PD-1 and were enriched within T follicular helper (Tfh) cells. We next investigated the role of LN CD32+ CD4 T cells in the HIV reservoir. Total HIV DNA was enriched in CD32+ and PD-1+ CD4 T cells compared to CD32− and PD-1− cells in both viremic and treated individuals, but there was no difference between CD32+ and PD-1+ cells. There was no enrichment of latently infected cells with inducible HIV-1 in CD32+ versus PD-1+ cells in antiretroviral therapy (ART)-treated individuals. HIV-1 transcription was then analyzed in LN memory CD4 T cell populations sorted on the basis of CD32 and PD-1 expression. CD32+ PD-1+ CD4 T cells were significantly enriched in cell-associated HIV RNA compared to CD32− PD-1− (averages of 5.2-fold in treated individuals and 86.6-fold in viremics), CD32+ PD-1− (2.2-fold in treated individuals and 4.3-fold in viremics), and CD32− PD-1+ (2.2-fold in ART-treated individuals and 4.6-fold in viremics) cell populations. Similar levels of HIV-1 transcription were found in CD32+ PD-1− and CD32− PD-1+ CD4 T cells. Interestingly, the proportion of CD32+ and PD-1+ CD4 T cells negatively correlated with CD4 T cell counts and length of therapy. Therefore, the expression of CD32 identifies, independently of PD-1, a CD4 T cell population with persistent HIV-1 transcription and coexpression of CD32 and PD-1, the CD4 T cell population with the highest levels of HIV-1 transcription in both viremic and treated individuals. IMPORTANCE The existence of long-lived latently infected resting memory CD4 T cells represents a major obstacle to the eradication of HIV infection. Identifying cell markers defining latently infected cells containing replication-competent virus is important in order to determine the mechanisms of HIV persistence and to develop novel therapeutic strategies to cure HIV infection. We provide evidence that PD-1 and CD32 may have a complementary role in better defining CD4 T cell populations infected with HIV-1. Furthermore, CD4 T cells coexpressing CD32 and PD-1 identify a CD4 T cell population with high levels of persistent HIV-1 transcription.

26 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KPKartika Padhan
Kartika Padhan
EMEirini Moysi
Eirini Moysi
Alessandra NotoAlessandra Noto
Alessandra Noto
ACAlexander Chassiakos
Alexander Chassiakos
KGKhader Ghneim
Khader Ghneim
CPConstantinos Petrovas
Constantinos Petrovas
The development of follicular helper CD4 T (TFH) cells is a dynamic process resulting in a heterogenous pool of TFH subsets. However, the cellular and molecular determinants of this heterogeneity and the possible mechanistic links between them is not clear. We found that human TFH differentiation is associated with significant changes in phenotypic, chemokine, functional, metabolic and transcriptional profile. Furthermore, this differentiation was associated with distinct positioning to follicular proliferating B cells. Single-cell T cell receptor (TCR) clonotype analysis indicated the transitioning toward PD-1hiCD57hi phenotype. Furthermore, the differentiation of TFH cells was associated with significant reduction in TCR level and drastic changes in immunological synapse formation. TFH synapse lacks a tight cSMAC (central supra molecular activation Cluster) but displays the TCR in peripheral microclusters, which are potentially advantageous in the ability of germinal center (GC) B cells to receive necessary help. Our data reveal significant aspects of human TFH heterogeneity and suggest that the PD-1hiCD57hi TFH cells, in particular, are endowed with distinctive programming and spatial positioning for optimal GC B cell help. Significance We characterized the heterogeneity of human TFH cells at a cellular, molecular, functional, and positional level and revealed possible mechanistic links between relevant determinants of this heterogeneity. Linking the topology with specific molecular profile and function is a key aspect in the understanding of the role of particular TFH cell subsets in the pathogenesis of relevant diseases and the delivery of optimal help to GC B cells for the development of potent neutralizing antibodies.

28 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Alessandra NotoAlessandra Noto
Alessandra Noto
VJVictor Joo
Victor Joo
AMAntonio Mancarella
Antonio Mancarella
MSMadeleine Suffiotti
Madeleine Suffiotti
CPCeline Pellaton
Celine Pellaton
GPGiuseppe Pantaleo
Giuseppe Pantaleo
A better understanding of the immunological markers associated with long-lasting immune responses to SARS-CoV-2 infection is of paramount importance. In the present study, we characterized SARS-CoV-2-specific humoral responses in hospitalized (ICU and non-ICU) and non-hospitalized individuals at six months post-onset of symptoms (POS) (N = 95). We showed that the proportion of individuals with detectable anti-SARS-CoV-2 IgG or neutralizing (NAb) responses and the titers of antibodies were significantly reduced in non-hospitalized individuals, compared to ICU- or non-ICU-hospitalized individuals at 6 months POS. Interestingly, SARS-CoV-2-specific memory B cells persist at 6 months POS in both ICU and non-ICU patients and were enriched in cells harboring an activated and/or exhausted phenotype. The frequency/phenotype of SARS-CoV-2-specific memory B cells and the magnitude of IgG or NAb responses at 6 months POS correlated with the serum immune signature detected at patient admission. In particular, the serum levels of CXCL13, IL-1RA, and G-CSF directly correlated with the frequency of Spike-specific B cells and the magnitude of Spike-specific IgG or NAb, while the serum levels of CXCL12 showed an antagonizing effect. Our results indicate that the balance between CXCL12 and CXCL13 is an early marker associated with the magnitude and the quality of the SARS-CoV-2 humoral memory.

1 May 2017 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
PDF file
Alessandra NotoAlessandra Noto
Alessandra Noto
GPGiuseppe Pantaleo
Giuseppe Pantaleo
The purpose of the present review is to provide an update on the current development in the field of broadly neutralizing antibodies (bNabs) and their potential use in the prevention and therapeutic settings, and an evaluation of the B-cell abnormalities that may impair antibody responses in HIV infection. Major advances have been achieved in the characterization of bNabs directed against different vulnerable regions of HIV Envelope (Env). Recent observations have clearly demonstrated the ability of bNabs to prevent HIV infection in the nonhuman primate model of HIV infection and to suppress viremia in individuals with chronic HIV infection in the absence of antiretroviral therapy. Furthermore, substantial advances have also been obtained in the development of HIV Env proteins and immunization strategies inducing bNabs in small animal models. Several studies have also shed light on the B-cell abnormalities associated with the viremic phase of HIV infection that cause impaired B-cell maturation and antibody responses. Of note, preliminary observations have provided evidence for a correlation between the expansion of a specific population of B cells, for example, germinal center B cells, the expansion of T follicular helper cells (Tfh), and the generation of neutralizing antibodies. The recent observations on the antiviral effects of bNabs in vivo indicate that bNabs may play a central role in both the prevention and the therapeutic settings. The identification of the role of germinal center B cells and Tfh cells as critical components of the immune response leading to the generation of neutralizing antibodies, will allow the development of specific immunization strategies for the stimulation of germinal center B cells and Tfh cells. A lot of work still remains to be done for the delineation of B-cell and Tfh cell biology from human lymphoid tissues and in the development of HIV Env proteins and immunization strategies leading to the generation of bNabs.

11 April 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
Elias A. SaidElias A. Said
Elias A. Said
Alessandra NotoAlessandra Noto
Alessandra Noto
SCSylvain Cardinaud
Sylvain Cardinaud
AAAli Al-Jabri
Ali Al-Jabri
Vaccines are indispensable tools in the battle against infectious diseases and hold great potential in combating a myriad of other diseases

24 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
Alessandra NotoAlessandra Noto
Alessandra Noto
Francesco Andrea ProcopioFrancesco Andrea Procopio
Francesco Andrea Procopio
RBRiddhima Banga
Riddhima Banga
MSMadeleine Suffiotti
Madeleine Suffiotti
JCJean-Marc Corpataux
Jean-Marc Corpataux
GPGiuseppe Pantaleo
Giuseppe Pantaleo
A recent study conducted in blood has proposed CD32 as the marker identifying the ‘elusive’ HIV reservoir. We have investigated the distribution of CD32 + CD4 T cells in blood and lymph nodes(LNs) of healthy HIV-1 uninfected, viremic untreated and long-term treated HIV-1 infected individuals and their relationship with PD-1 + CD4 T cells. The frequency of CD32 + CD4 T cells was increased in viremic as compared to treated individuals in LNs and a large proportion(up to 50%) of CD32 + cells co-expressed PD-1 and were enriched within T follicular helper cells(Tfh) cells. We next investigated the role of LN CD32 + CD4 T cells in the HIV reservoir. Total HIV DNA was enriched in CD32 + and PD-1 + CD4 T cells as compared to CD32 - and PD-1 - cells in both viremic and treated individuals but there was no difference between CD32 + and PD-1 + cells. There was not enrichment of latently infected cells with inducible HIV-1 in CD32 + versus PD-1 + cells in ART treated individuals. HIV-1 transcription was then analyzed in LN memory CD4 T cell populations sorted on the basis of CD32 and PD-1 expression. CD32 + PD-1 + CD4 T cells were significantly enriched in cell associated HIV RNA as compared to CD32 - PD-1 -( average 5.2 fold in treated and 86.6 fold in viremics), to CD32 + PD-1 -( 2.2 fold in treated and 4.3 fold in viremics) and to CD32 - PD-1 + cell populations(2.2 fold in ART treated and 4.6 fold in viremics). Similar levels of HIV-1 transcription were found in CD32 + PD-1 - and CD32 - PD-1 + CD4 T cells. Interestingly, the proportion of CD32 + and PD-1 + CD4 T cells negatively correlated with CD4 T cell counts and length of therapy while positively correlated with viremia. Therefore, the expression of CD32 identifies, independently of PD-1, a CD4 T cell population with persistent HIV-1 transcription and CD32 and PD-1 co-expression the CD4 T cell population with the highest levels of HIV-1 transcription in both viremic and treated individuals. Importance: The existence of long-lived latently infected resting memory CD4 T cells represents a major obstacle to the eradication of HIV infection. Identifying cell markers defining latently infected cells containing replication competent virus is important in order to determine the mechanisms of HIV persistence and to develop novel therapeutic strategies to cure HIV infection. We provide evidence that PD-1 and CD32 may have a complementary role in better defining CD4 T cell populations infected with HIV-1. Furthermore, CD4 T cells co-expressing CD32 and PD-1 identify a CD4 T cell population with high levels of persistent HIV-1 transcription.